Synthorx, Inc. Common Stock
THOR
THOR was delisted on the 22nd of January, 2020.
20 hedge funds and large institutions have $361M invested in Synthorx, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$141M |
| 2 |
O
OrbiMed
New York
|
+$77.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.2M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$27M |
| 5 |
Goldman Sachs
New York
|
+$9.48M |
Top Sellers
THOR Hedge Fund Activity: Q4 2018 in Review
20 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Synthorx, Inc. Common Stock (THOR) for Q4 2018, worth a combined $361M.
Buyers outnumbered sellers: 20 funds opened new THOR positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $141M.
- 20 institutional investors held Synthorx, Inc. Common Stock (THOR) as of Q4 2018, up from 0 in Q3 2018.
- Funds reported $361M of Synthorx, Inc. Common Stock stock for Q4 2018.
- 20 funds opened new Synthorx, Inc. Common Stock positions in Q4 2018 and 0 closed out, a net change of +20 holders.
- The largest Synthorx, Inc. Common Stock buyer in Q4 2018 was RA Capital Management, an estimated $141M added.
Based on aggregated 13F filings for Q4 2018.